<p>随着 2026 年的开始，亚洲市场正在应对一个复杂的环境，主要指数表现不一，对经济复苏持谨慎乐观态度。在这种气候下，识别被低估的股票对于希望利用潜在增长机会的投资者来说，可以是一项战略性举措，特别是那些被估计显著低于其内在价值的股票。</p>
<h3>基于现金流的亚洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>西安国际医疗投资（SZSE:000516）</td>
<td>CN¥4.72</td>
<td>CN¥9.38</td>
<td>49.7%</td>
</tr>
<tr>
<td>厦门特宝生物科技（SHSE:688278）</td>
<td>CN¥83.40</td>
<td>CN¥162.39</td>
<td>48.6%</td>
</tr>
<tr>
<td>高乐生物（TSE:4974）</td>
<td>¥795.00</td>
<td>¥1579.24</td>
<td>49.7%</td>
</tr>
<tr>
<td>四川凯伦生物制药（SEHK:6990）</td>
<td>HK$432.00</td>
<td>HK$851.22</td>
<td>49.2%</td>
</tr>
<tr>
<td>Plus Alpha Consulting Ltd（TSE:4071）</td>
<td>¥2332.00</td>
<td>¥4591.95</td>
<td>49.2%</td>
</tr>
<tr>
<td>Mobvista（SEHK:1860）</td>
<td>HK$15.43</td>
<td>HK$30.64</td>
<td>49.6%</td>
</tr>
<tr>
<td>美图（SEHK:1357）</td>
<td>HK$7.59</td>
<td>HK$14.75</td>
<td>48.5%</td>
</tr>
<tr>
<td>Kuraray（TSE:3405）</td>
<td>¥1599.50</td>
<td>¥3167.05</td>
<td>49.5%</td>
</tr>
<tr>
<td>大巨人纤维服装（TWSE:4441）</td>
<td>NT$234.50</td>
<td>NT$457.28</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS（TSE:7085）</td>
<td>¥794.00</td>
<td>¥1582.86</td>
<td>49.8%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 260 只被低估的亚洲股票的完整列表。</p>
<p>我们将查看我们筛选工具中的一些最佳选择。</p>
<h2>三星电子（KOSE:A005930）</h2>
<p><strong>概述：</strong> 三星电子有限公司在消费电子、信息技术和移动通信以及设备解决方案领域全球运营，市值为₩903.85 万亿。</p>
<p><strong>运营：</strong> 公司的收入部分包括设备体验（DX）为₩184.19 万亿，设备解决方案（DS）为₩116.22 万亿，SDC 为₩28.47 亿，Harman 为₩15.13 亿。</p>
<p><strong>公允价值折扣估计：</strong> 43.6%</p>
<p>三星电子的交易价格为₩138,100，显著低于其估计的公允价值₩244,763.67。尽管预计年收入增长 12.3%——超过韩国市场的 11.4%——但其股本回报率预计将保持在 10.4% 的低位。预计未来三年盈利将显著增长，年增长率超过 40%，超过更广泛市场的 31.8% 增长率。近期的产品创新和战略合作增强了其综合生态系统和人工智能能力。</p>
<ul>
<li>根据我们的盈利增长报告，三星电子可能准备扩张。</li>
<li>点击探索我们在三星电子资产负债表健康报告中的详细分析。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23ed9cb7-f310-45a5-a486-e97223e0eeac/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23ed9cb7-f310-45a5-a486-e97223e0eeac/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>KOSE:A005930 截至 2026 年 1 月的折现现金流</p>
<h2>四川凯伦生物制药（SEHK:6990）</h2>
<p><strong>概述：</strong> 四川凯伦生物制药有限公司是一家生物制药公司，专注于肿瘤学和免疫学的新药研究、开发、生产和商业化，市值约为 HK$100.74 亿。</p>
<p><strong>运营：</strong> 该公司通过其制药部门产生约 CN¥15 亿的收入，其中包括肿瘤学和免疫学的新药。</p>
<p><strong>公允价值折扣估计：</strong> 49.2%</p>
<p>四川凯伦生物制药的交易价格为 HK$432，远低于其估计的公允价值 HK$851.22。预计该公司的收入将以 32.1% 的年增长率显著增长，超过香港市场的 8.3% 增长率。预计在三年内实现盈利，股本回报率预计高达 27.5%。近期在抗体药物偶联物方面的突破和战略合作可能会增强其财务前景，并加快在中国的产品审批。</p>
<ul>
<li>我们的盈利增长报告揭示了四川凯伦生物制药未来结果显著增长的潜力。</li>
<li>点击这里了解四川凯伦生物制药的全面财务健康报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6f0d4402-5dd1-4a56-9456-4353239b7bb5/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6f0d4402-5dd1-4a56-9456-4353239b7bb5/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:6990 截至 2026 年 1 月的折现现金流</p>
<h2>武汉光电（SZSE:002414）</h2>
<p><strong>概述：</strong> 武汉光电有限公司设计、制造、营销和销售红外热成像探测器和模块以及电光系统，市值为 CN¥68.93 亿。</p>
<p><strong>运营：</strong> 武汉光电有限公司通过生产和分销红外热成像探测器、模块和电光系统在国内和国际市场上产生收入。</p>
<p><strong>公允价值折扣估计：</strong> 35.9%</p>
<p>武汉光电的交易价格为 CN¥16.14，显著低于其估计的公允价值 CN¥25.18，表明其可能在现金流基础上被低估。该公司表现出强劲的财务业绩，2025 年前九个月收入达到 CNY 30.7 亿，净收入从去年同期的 CNY 5.02 亿增加到 CNY 5.82 亿。预测显示年盈利增长超过 61%，超过中国市场的平均增长率。</p>
<ul>
<li>我们最近的增长报告提供了武汉光电业务前景的良好预测。</li>
<li>点击这里访问我们的完整资产负债表健康报告，以了解武汉光电的动态。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:002414 截至 2026 年 1 月的折现现金流</p>
<h2>让它发生</h2>
<ul>
<li>在这里浏览 260 只基于现金流的被低估亚洲股票的完整库存。</li>
<li>你是否已经投资于这些公司？利用 Simply Wall St 的投资组合，密切关注影响你投资的市场动态。</li>
<li>通过 Simply Wall St 解锁知情投资的力量，这是你在全球股市中导航的免费指南。</li>
</ul>
<h2>考虑其他策略？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠收入来源的稳健分红股票来分散你的投资组合，以应对潜在的市场波动。</li>
<li>用显示强劲增长潜力的公司来充实你的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。它不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。</strong> 我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

三星电子

特宝生物

<p>截至 2026 年，亚洲市场表现参差不齐，促使投资者寻求被低估的股票。值得关注的公司包括西安国际医疗投资、厦门特宝生物和四川凯伦生物科技，预计它们的内在价值显著低于市场价格，折扣范围在 48.5% 到 49.7% 之间。三星电子和武汉导热红外线也被提及，交易价格低于其公允价值，并预计将实现强劲的盈利增长。这些见解表明，随着公司展现出良好的财务预测和增长潜力，亚洲市场存在潜在的投资机会</p>

<p>As 2026 begins, Asian markets are navigating a complex landscape marked by mixed performances across major indices and cautious optimism about economic recovery. In this climate, identifying undervalued stocks can be a strategic move for investors looking to capitalize on potential growth opportunities, particularly those estimated to be significantly below their intrinsic value.</p>
<div class="lb-trans"><p>随着 2026 年的开始，亚洲市场正在应对一个复杂的环境，主要指数表现不一，对经济复苏持谨慎乐观态度。在这种气候下，识别被低估的股票对于希望利用潜在增长机会的投资者来说，可以是一项战略性举措，特别是那些被估计显著低于其内在价值的股票。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基于现金流的亚洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Xi'an International Medical Investment (SZSE:000516)</td>
<td>CN¥4.72</td>
<td>CN¥9.38</td>
<td>49.7%</td>
</tr>
<tr>
<td>Xiamen Amoytop Biotech (SHSE:688278)</td>
<td>CN¥83.40</td>
<td>CN¥162.39</td>
<td>48.6%</td>
</tr>
<tr>
<td>Takara Bio (TSE:4974)</td>
<td>¥795.00</td>
<td>¥1579.24</td>
<td>49.7%</td>
</tr>
<tr>
<td>Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)</td>
<td>HK$432.00</td>
<td>HK$851.22</td>
<td>49.2%</td>
</tr>
<tr>
<td>Plus Alpha ConsultingLtd (TSE:4071)</td>
<td>¥2332.00</td>
<td>¥4591.95</td>
<td>49.2%</td>
</tr>
<tr>
<td>Mobvista (SEHK:1860)</td>
<td>HK$15.43</td>
<td>HK$30.64</td>
<td>49.6%</td>
</tr>
<tr>
<td>Meitu (SEHK:1357)</td>
<td>HK$7.59</td>
<td>HK$14.75</td>
<td>48.5%</td>
</tr>
<tr>
<td>Kuraray (TSE:3405)</td>
<td>¥1599.50</td>
<td>¥3167.05</td>
<td>49.5%</td>
</tr>
<tr>
<td>Great Giant Fibre Garment (TWSE:4441)</td>
<td>NT$234.50</td>
<td>NT$457.28</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥794.00</td>
<td>¥1582.86</td>
<td>49.8%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>西安国际医疗投资（SZSE:000516）</td>
<td>CN¥4.72</td>
<td>CN¥9.38</td>
<td>49.7%</td>
</tr>
<tr>
<td>厦门特宝生物科技（SHSE:688278）</td>
<td>CN¥83.40</td>
<td>CN¥162.39</td>
<td>48.6%</td>
</tr>
<tr>
<td>高乐生物（TSE:4974）</td>
<td>¥795.00</td>
<td>¥1579.24</td>
<td>49.7%</td>
</tr>
<tr>
<td>四川凯伦生物制药（SEHK:6990）</td>
<td>HK$432.00</td>
<td>HK$851.22</td>
<td>49.2%</td>
</tr>
<tr>
<td>Plus Alpha Consulting Ltd（TSE:4071）</td>
<td>¥2332.00</td>
<td>¥4591.95</td>
<td>49.2%</td>
</tr>
<tr>
<td>Mobvista（SEHK:1860）</td>
<td>HK$15.43</td>
<td>HK$30.64</td>
<td>49.6%</td>
</tr>
<tr>
<td>美图（SEHK:1357）</td>
<td>HK$7.59</td>
<td>HK$14.75</td>
<td>48.5%</td>
</tr>
<tr>
<td>Kuraray（TSE:3405）</td>
<td>¥1599.50</td>
<td>¥3167.05</td>
<td>49.5%</td>
</tr>
<tr>
<td>大巨人纤维服装（TWSE:4441）</td>
<td>NT$234.50</td>
<td>NT$457.28</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS（TSE:7085）</td>
<td>¥794.00</td>
<td>¥1582.86</td>
<td>49.8%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 260 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 260 只被低估的亚洲股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看我们筛选工具中的一些最佳选择。</p>
</div><h2>Samsung Electronics (KOSE:A005930)</h2>
<div class="lb-trans"><h2>三星电子（KOSE:A005930）</h2>
</div><p><strong>Overview:</strong> Samsung Electronics Co., Ltd. operates globally in consumer electronics, information technology and mobile communications, and device solutions, with a market cap of ₩903.85 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 三星电子有限公司在消费电子、信息技术和移动通信以及设备解决方案领域全球运营，市值为₩903.85 万亿。</p>
</div><p><strong>Operations:</strong> The company's revenue segments consist of Device Experience (DX) at ₩184.19 billion, Device Solutions (DS) at ₩116.22 billion, SDC at ₩28.47 million, and Harman at ₩15.13 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入部分包括设备体验（DX）为₩184.19 万亿，设备解决方案（DS）为₩116.22 万亿，SDC 为₩28.47 亿，Harman 为₩15.13 亿。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 43.6%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 43.6%</p>
</div><p>Samsung Electronics is trading at ₩138,100, significantly below its estimated fair value of ₩244,763.67. Despite a forecasted revenue growth of 12.3% annually—outpacing the Korean market's 11.4%—its Return on Equity is expected to remain low at 10.4%. Earnings are projected to grow significantly by over 40% annually in the next three years, surpassing the broader market's growth rate of 31.8%. Recent product innovations and strategic partnerships enhance its integrated ecosystem and AI capabilities.</p>
<div class="lb-trans"><p>三星电子的交易价格为₩138,100，显著低于其估计的公允价值₩244,763.67。尽管预计年收入增长 12.3%——超过韩国市场的 11.4%——但其股本回报率预计将保持在 10.4% 的低位。预计未来三年盈利将显著增长，年增长率超过 40%，超过更广泛市场的 31.8% 增长率。近期的产品创新和战略合作增强了其综合生态系统和人工智能能力。</p>
</div><ul>
<li>According our earnings growth report, there's an indication that Samsung Electronics might be ready to expand.</li>
<li>Click to explore a detailed breakdown of our findings in Samsung Electronics' balance sheet health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>根据我们的盈利增长报告，三星电子可能准备扩张。</li>
<li>点击探索我们在三星电子资产负债表健康报告中的详细分析。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23ed9cb7-f310-45a5-a486-e97223e0eeac/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/23ed9cb7-f310-45a5-a486-e97223e0eeac/chart/dcf?theme=light"/></p>
<p>KOSE:A005930 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>KOSE:A005930 截至 2026 年 1 月的折现现金流</p>
</div><h2>Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)</h2>
<div class="lb-trans"><h2>四川凯伦生物制药（SEHK:6990）</h2>
</div><p><strong>Overview:</strong> Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company involved in the research, development, manufacturing, and commercialization of novel drugs focusing on oncology and immunology both in China and internationally, with a market cap of approximately HK$100.74 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 四川凯伦生物制药有限公司是一家生物制药公司，专注于肿瘤学和免疫学的新药研究、开发、生产和商业化，市值约为 HK$100.74 亿。</p>
</div><p><strong>Operations:</strong> The company generates revenue of approximately CN¥1.50 billion from its pharmaceuticals segment, which includes novel drugs in oncology and immunology.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过其制药部门产生约 CN¥15 亿的收入，其中包括肿瘤学和免疫学的新药。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 49.2%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 49.2%</p>
</div><p>Sichuan Kelun-Biotech Biopharmaceutical is trading at HK$432, well below its estimated fair value of HK$851.22. The company's revenue is projected to grow significantly at 32.1% annually, surpassing the Hong Kong market's growth rate of 8.3%. It is expected to become profitable within three years with a high Return on Equity forecasted at 27.5%. Recent breakthroughs in antibody-drug conjugates and strategic collaborations could bolster its financial outlook and expedite product approvals in China.</p>
<div class="lb-trans"><p>四川凯伦生物制药的交易价格为 HK$432，远低于其估计的公允价值 HK$851.22。预计该公司的收入将以 32.1% 的年增长率显著增长，超过香港市场的 8.3% 增长率。预计在三年内实现盈利，股本回报率预计高达 27.5%。近期在抗体药物偶联物方面的突破和战略合作可能会增强其财务前景，并加快在中国的产品审批。</p>
</div><ul>
<li>Our earnings growth report unveils the potential for significant increases in Sichuan Kelun-Biotech Biopharmaceutical's future results.</li>
<li>Navigate through the intricacies of Sichuan Kelun-Biotech Biopharmaceutical with our comprehensive financial health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的盈利增长报告揭示了四川凯伦生物制药未来结果显著增长的潜力。</li>
<li>点击这里了解四川凯伦生物制药的全面财务健康报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6f0d4402-5dd1-4a56-9456-4353239b7bb5/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/6f0d4402-5dd1-4a56-9456-4353239b7bb5/chart/dcf?theme=light"/></p>
<p>SEHK:6990 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:6990 截至 2026 年 1 月的折现现金流</p>
</div><h2>Wuhan Guide Infrared (SZSE:002414)</h2>
<div class="lb-trans"><h2>武汉光电（SZSE:002414）</h2>
</div><p><strong>Overview:</strong> Wuhan Guide Infrared Co., Ltd. designs, manufactures, markets, and sells infrared thermal imaging detectors and modules as well as electro-optical systems both in China and internationally, with a market cap of CN¥68.93 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 武汉光电有限公司设计、制造、营销和销售红外热成像探测器和模块以及电光系统，市值为 CN¥68.93 亿。</p>
</div><p><strong>Operations:</strong> Wuhan Guide Infrared Co., Ltd. generates revenue through the production and distribution of infrared thermal imaging detectors, modules, and electro-optical systems across domestic and international markets.</p>
<div class="lb-trans"><p><strong>运营：</strong> 武汉光电有限公司通过生产和分销红外热成像探测器、模块和电光系统在国内和国际市场上产生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 35.9%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 35.9%</p>
</div><p>Wuhan Guide Infrared is trading at CN¥16.14, significantly below its estimated fair value of CN¥25.18, suggesting it may be undervalued based on cash flows. The company has shown strong financial performance, with revenue reaching CNY 3.07 billion for the first nine months of 2025 and net income increasing to CNY 581.94 million from CNY 50.21 million a year ago. Forecasts indicate robust annual earnings growth of over 61%, outpacing the Chinese market's average growth rate.</p>
<div class="lb-trans"><p>武汉光电的交易价格为 CN¥16.14，显著低于其估计的公允价值 CN¥25.18，表明其可能在现金流基础上被低估。该公司表现出强劲的财务业绩，2025 年前九个月收入达到 CNY 30.7 亿，净收入从去年同期的 CNY 5.02 亿增加到 CNY 5.82 亿。预测显示年盈利增长超过 61%，超过中国市场的平均增长率。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for Wuhan Guide Infrared's business outlook.</li>
<li>Click here and access our complete balance sheet health report to understand the dynamics of Wuhan Guide Infrared.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们最近的增长报告提供了武汉光电业务前景的良好预测。</li>
<li>点击这里访问我们的完整资产负债表健康报告，以了解武汉光电的动态。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/dcf?theme=light"/></p>
<p>SZSE:002414 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SZSE:002414 截至 2026 年 1 月的折现现金流</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>让它发生</h2>
</div><ul>
<li>Navigate through the entire inventory of 260 Undervalued Asian Stocks Based On Cash Flows here.</li>
<li>Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.</li>
<li>Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里浏览 260 只基于现金流的被低估亚洲股票的完整库存。</li>
<li>你是否已经投资于这些公司？利用 Simply Wall St 的投资组合，密切关注影响你投资的市场动态。</li>
<li>通过 Simply Wall St 解锁知情投资的力量，这是你在全球股市中导航的免费指南。</li>
</ul>
</div><h2>Contemplating Other Strategies?</h2>
<div class="lb-trans"><h2>考虑其他策略？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠收入来源的稳健分红股票来分散你的投资组合，以应对潜在的市场波动。</li>
<li>用显示强劲增长潜力的公司来充实你的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。它不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。</strong> 我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

3 只亚洲股票被估计低于其内在价值 35.9% 至 49.2%